Golimumab for the treatment of ulcerative colitis

Introduction: Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Flamant, Mathurin, Paul, Stephane, Roblin, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Drug Evaluation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490638/
https://www.ncbi.nlm.nih.gov/pubmed/28472597
http://dx.doi.org/10.1080/14712598.2017.1327576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490638/
https://www.ncbi.nlm.nih.gov/pubmed/28472597
http://dx.doi.org/10.1080/14712598.2017.1327576

Ejemplares similares